The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
T-cell expression of programmed death receptor-1 (PD-1) down-regulates the immune response against malignancy by interacting with cognate ligands (eg, PD-L1) on tumor cells; however, little is known regarding PD-1 and natural killer (NK) cells. NK cells exert cytotoxicity against multiple myeloma (MM), an effect enhanced through novel therapies. We show that NK cells from MM patients express PD-1 whereas normal NK cells do not and confirm PD-L1 on primary MM cells. Engagement of PD-1 with PD-L1 should down-modulate the NK-cell versus MM effect. We demonstrate that CT-011, a novel anti-PD-1 antibody, enhances human NK-cell function against autologous, primary MM cells, seemingly through effects on NK-cell trafficking, immune complex formation with MM cells, and cytotoxicity specifically toward PD-L1(+) MM tumor cells but not normal cells. We show that lenalidomide down-regulates PD-L1 on primary MM cells and may augment CT-011's enhancement of NK-cell function against MM. We demonstrate a role for the PD-1/PD-L1 signaling axis in the NK-cell immune response against MM and a role for CT-011 in enhancing the NK-cell versus MM effect. A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered.
Benson
Don M
DM
Division of Hematology/Oncology, The Ohio State University Medical Center, Columbus, OH, USA.
Bakan
Courtney E
CE
Mishra
Anjali
A
Hofmeister
Craig C
CC
Efebera
Yvonne
Y
Becknell
Brian
B
Baiocchi
Robert A
RA
Zhang
Jianying
J
Yu
Jianhua
J
Smith
Megan K
MK
Greenfield
Carli N
CN
Porcu
Pierluigi
P
Devine
Steven M
SM
Rotem-Yehudar
Rinat
R
Lozanski
Gerard
G
Byrd
John C
JC
Caligiuri
Michael A
MA
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000936:Antigen-Antibody Complex / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism*; D060890:B7-H1 Antigen; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor; D019718:Receptors, CXCR4 / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D060890:B7-H1 Antigen; C423236:CD274 protein, human; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D019718:Receptors, CXCR4; D013792:Thalidomide; D007371:Interferon-gamma; D000077269:Lenalidomide
Eur J Immunol. 2002 Mar;32(3):634-43
11857337
Cancer Immunol Immunother. 2008 Dec;57(12):1849-59
18392823
Annu Rev Immunol. 2008;26:677-704
18173375
Blood. 2003 Sep 15;102(6):1951-8
12730102
Int J Clin Lab Res. 1997;27(1):48-54
9144027
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90
18202175
Cancer Res. 1994 Nov 15;54(22):5793-6
7954401
Blood. 2001 Jul 1;98(1):210-6
11418482
Blood. 2000 Jan 15;95(2):610-8
10627470
Eur J Haematol. 1990 Sep;45(3):153-7
1699786
J Exp Med. 2003 Sep 15;198(6):851-62
12975453
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
J Leukoc Biol. 2002 Feb;71(2):173-83
11818437
APMIS. 1991 Apr;99(4):340-6
2036217
Blood. 2009 Sep 24;114(13):2667-77
19553639
J Immunol. 2003 Feb 1;170(3):1257-66
12538684
J Clin Oncol. 2008 May 20;26(15):2519-25
18427150
Cancer Res. 2007 Sep 15;67(18):8444-9
17875681
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
12218188
J Immunol. 2008 Nov 15;181(10):6738-46
18981091
J Immunol Methods. 2001 Jul 1;253(1-2):177-87
11384679
Cancer Res. 2005 Mar 1;65(5):1700-9
15753365
Immunol Rev. 2006 Dec;214:73-91
17100877
Blood. 2001 Jan 15;97(2):346-51
11154207
Blood. 2008 Feb 1;111(3):1309-17
17947507
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5756-60
9159146
J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32
12649301
Br J Haematol. 2005 Jan;128(2):192-203
15638853
Blood. 2005 Jan 1;105(1):251-8
15328155
J Transl Med. 2004 Sep 20;2(1):31
15380049
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
15297412
Cancer Immunol Immunother. 1995 Jun;40(6):376-82
7627994
Br J Haematol. 1996 Apr;93(1):81-8
8611480
Int J Cancer. 1984 Sep 15;34(3):375-81
6592156
Acta Haematol. 1997;98(3):150-4
9352746
Mol Cell Biol. 2005 Nov;25(21):9543-53
16227604
Clin Cancer Res. 2008 May 15;14(10):3044-51
18483370
J Immunol. 2004 Jul 15;173(2):945-54
15240681
Mol Cancer Ther. 2002 May;1(7):539-44
12479272
Cancer Res. 2003 Oct 1;63(19):6501-5
14559843
Blood. 2007 Apr 1;109(7):2708-17
17119115
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
17360651
Blood. 2007 Jul 1;110(1):296-304
17363736
Blood. 2009 Mar 19;113(12):2706-14
19060242
Blood. 2006 May 15;107(10):3940-9
16410445
J Immunol Methods. 2001 Mar 1;249(1-2):99-110
11226468
Am J Hematol. 1992 Feb;39(2):84-9
1550111
Cancer Res. 2005 Dec 15;65(24):11712-20
16357183